Berberine nanomicelles attenuate cirrhotic cardiomyopathy in rats: Possible involvement of the NO-cGMP signaling

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 244

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_NAMJ-7-4_006

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Objective(s): In cirrhotic cardiomyopathy, a rise in pro-inflammatory cytokines results in the up-regulation of inducible nitric oxide synthase (iNOS), and the overproductions of nitric oxide (NO) and cyclic guanosine ۳’, ۵’ monophosphate (cGMP). Berberine (BBR), an isoquinoline-derived alkaloid isolated from Rhizoma coptidis, possesses anti-inflammatory, anti-oxidative, and cardioprotective properties. In this study, the effect of BBR-loaded micelles in a rat model of cirrhotic cardiomyopathy resulted from bile duct-ligation (BDL) was examined. Further, a possible role for NO-cGMP signaling was clarified. Materials and Methods: Cirrhotic rats were orally treated with BBR-loaded micelles (۵۰ mg/kg), free BBR (۵۰ and ۱۰۰ mg/kg) and silymarin (۱۰۰ mg/kg). A selective iNOS inhibitor, aminoguanidine (AG) ۱۰۰ mg/kg, i.p., was administered. iNOS expression and nitrite concentration were calculated using immunohistochemistry (IHC) and Griess reagent methods, respectively. Besides, ventricular tumor necrosis factor-alpha (TNF-α), cGMP, and serum interleukin -۱beta (IL-۱β) were measured using ELISA kits. Results: TNF-α and IL-۱β, nitrite, cGMP, and the expression of iNOS increased significantly in BDL rats. However, BBR (۱۰۰ mg/kg), nanoBBR (۵۰ mg/kg), and silymarin markedly lowered the levels of these markers. Notably, AG increased the nanoBBR effect.Conclusion: This cardioprotective effect of nanoBBR probably mediated at least in part by down-regulations of the NO-cGMP pathway, and the inflammatory mediators.

کلیدواژه ها:

Bile duct-ligation ، Cardiomyopathy ، Nanoberberine ، Rat ، The NO- cGMP pathway

نویسندگان

Nahid Fakhraei

Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Seyyedeh Elaheh Mousavi

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Mahsa Sadeghi Adl

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University of Tehran, Iran (IAUPS)

Seyed Pouyan Pishva

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University of Tehran, Iran (IAUPS)

Fatemeh Tabarsa

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University of Tehran, Iran (IAUPS)

Seyed Mahdi Rezayat

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Amir Rashidian

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Ahmad Reza Dehpour

Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1.Ma Z, A Miyamoto, SS Lee. Role of altered beta-adrenoceptor ...
  • 2.Liu H, Z Ma, SS Lee. Contribution of nitric oxide ...
  • 3.Liu H, D Song, SS Lee. Role of heme oxygenase-carbon ...
  • 4.Rubio AR, MA Morales-Segura. Nitric oxide, an iceberg in cardiovascular ...
  • 5.Kumar A, B Paladugu, J Mensing, A Kumar, JE Parrillo. ...
  • 6.Guarner C, G Soriano, A Tomas, O Bulbena, MT Novella, ...
  • 7.Morales‐Ruiz M, W Jimenez, D Perez‐Sala, J Ros, A Leivas, ...
  • 8.Kelly RA, J-L Balligand, TW Smith. Nitric oxide and cardiac ...
  • 9.Herring N, EJ Danson, DJ Paterson. Cholinergic control of heart ...
  • 10.Mónica F, K Bian, F Murad. The Endothelium-Dependent Nitric Oxide–cGMP ...
  • 11.Račková L, M Májeková, D Košt’álová, M Štefek. Antiradical and ...
  • 12.Stermitz FR, P Lorenz, JN Tawara, LA Zenewicz, K Lewis. ...
  • 13.Tabeshpour J, M Imenshahidi, H Hosseinzadeh. A review of the ...
  • 14.Tan HL, KG Chan, P Pusparajah, A Duangjai, S Saokaew, ...
  • 15.Lee IA, YJ Hyun, DH Kim. Berberine ameliorates TNBS-induced colitis ...
  • 16.Xiao M, LN Men, MG Xu, GB Wang, HT Lv, ...
  • 17.Zhang BJ, D Xu, Y Guo, J Ping, Lb Chen, ...
  • 18.Chen K, G Li, F Geng, Z Zhang, J Li, ...
  • 19.Huang Z, Z Han, B Ye, Z Dai, P Shan, ...
  • 20.Lau CW, XQ Yao, ZY Chen, WH Ko, Y Huang. ...
  • 21.Zhang T, S Yang, J Du. Protective effects of berberine ...
  • 22.Gao J, Yq Tang, D z Dai, Y s Cheng, ...
  • 23.Qi M y, Y Feng, D z Dai, N Li, ...
  • 24.Zeng X H, X J Zeng, Y Y Li. Efficacy ...
  • 25.Pirillo A, A L Catapano, Berberine. a plant alkaloid with ...
  • 26.Shen R, J J Kim, M Yao, T A Elbayoumi. ...
  • 27.Chen W, S Wei, Y Yu, H Xue, F Yao, ...
  • 28.Allijn I E, B M Czarny, X Wang, S Y ...
  • 29.Khoshnoodi M, N Fakhraei, A R Dehpour. Possible involvement of ...
  • 30.Rao P R, R K Viswanath. Cardioprotective activity of silymarin ...
  • 31.Tuorkey M J, N I El Desouki, R A Kamel. ...
  • 32.Domitrović R, H Jakovac, G Blagojević. Hepatoprotective activity of berberine ...
  • 33.Pishva S P, E Mousavi, Z Mousavi, M R Jaafari, ...
  • 34.Ma Z, Y Zhang, P M Huet, S S Lee. ...
  • 35.Abbasi A, A Joharimoqaddam, N Faramarzi, M Khosravi, I Jahanzad, ...
  • 36.Fakhraei N, A H Abdolghaffari, B Delfan, A Abbasi, N ...
  • 37.Miranda K M, M G Espey, D A Wink. A ...
  • 38.Mousavi S E, S M Rezayat, M Nobakht, S S ...
  • 39.Saravi S S S, M Ghazi-Khansari, S E Mehr, M ...
  • 40.Yang Y Y, H Liu, S W Nam, G Kunos, ...
  • 41.Bortoluzzi A, G Ceolotto, E Gola, A Sticca, S Bova, ...
  • 42.Mani A R, A Nahavandi, M Moosavi, R Safarinejad, A ...
  • 43.Nahavandi A, A R Dehpour, A R Mani, H Homayounfar, ...
  • 44.Clements W, P Erwin, M McCaigue, I Halliday, G Barclay, ...
  • 45.Radomski M, R Palmer, S Moncada. Glucocorticoids inhibit the expression ...
  • 46.Namiranian K, M Samini, S E Mehr, S A Gaskari, ...
  • 47.Mani A R, S Ippolito, R Ollosson, K P Moore. ...
  • 48.van Obbergh, L Y Vallieres, G Blaise. Cardiac modifications occurring ...
  • 49.GARCÍA-ESTAÑ J, M C ORTIZ. Nitric oxide and renal and ...
  • 50.Xiong C, Y Z Wu, Y Zhang, Z X Wu, ...
  • 51.Zhao X, J Zhang, N Tong, X Liao, E Wang, ...
  • 52.Li X, M Gao, X Zhang, J Xie, J Xue, ...
  • 53.Chang W, M Zhang, J Li, Z Meng, D Xiao, ...
  • 54.Wang, Q., M. Zhang, B. Liang, N. Shirwany, Y. Zhu, ...
  • 55.Chang W, K Li, F Guan, F Yao, Y Yu, ...
  • 56.Yu L, Q Li, B Yu, Y Yang, Z Jin, ...
  • 57.Dong S F, Y Hong, M Liu, Y Z Hao, ...
  • 58.Wang Y Y, Huang KS Lam, Y Li, W T ...
  • 59.Zeng X, Y Li. Clinical observations of the effect of ...
  • نمایش کامل مراجع